Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer

The Estrogen Receptor Negative-Progesterone Receptor Positive Breast Carcinoma is a Biological Entity and not a Technical Artifact

(2012) Char Hong Ng et al.   Asian Pacific Journal of Cancer Prevention

Estrogen Receptor Negative and Progesterone Receptor Positive Breast Carcinomas—How Frequent are they?

(2011) Gábor Cserni et al.   PATHOLOGY & ONCOLOGY RESEARCH

Acquired endocrine resistance in breast cancer: implications for tumour metastasis

(2010) Edd Hayes   Frontiers in Bioscience-Landmark

In vitro characterization of ZK 230211—A type III progesterone receptor antagonist with enhanced antiproliferative properties

(2010) Wiebke Afhüppe et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression

(2010) L. Busia et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

A 2009 Update on the Treatment of Patients with Hormone Receptor—Positive Breast Cancer

(2009) Susan J. Cleator et al.   Clinical Breast Cancer

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment

(2008) Ke-da Yu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY